layout.fixed.naaccr.doc.naaccr22.rxHospBrm.html Maven / Gradle / Ivy

Go to download

Show more of this group Show more artifacts with this name
Show all versions of layout Show documentation

Framework that allows defining file formats (layouts) and use them to read and write data files.

There is a newer version: 6.0


    
        Item #
        Length
        Source of Standard
        Year Implemented
        Version Implemented
        Year Retired
        Version Retired
    
    
        720
        2
        CoC
        
        
        
        
    



NAACCR XML: Tumor.rxHospBrm


Alternate Names

   Immunotherapy at this Facility (CoC)


Description
Records whether immunotherapeutic agents (biologic response modifiers) were administered as first-course treatment at this facility or the reason they were not given. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host’s response to tumor cells.
Rationale
Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of immunotherapeutic agents given as part of the first course of therapy. Furthermore, it is useful to know the reason immunotherapy was not administered when evaluating quality of care.

If central registries wish to study the treatment given at particular facilities, the facility-level treatment fields must be used. The summary treatment fields, conversely, combine information for all facilities that provide first course of treatment for the tumor. Facility-specific fields allow studies of detailed referral patterns and treatment by type of healthcare setting. Knowing what part of the treatment was given at a particular facility also helps resolve consolidation issues.


    Note: Prior to 2013, targeted therapies that invoke an immune response, such as Herceptin, had been coded as chemotherapy. Effective with cases diagnosed January 1, 2013, and forward these therapies are classified as biological response modifiers. Coding instructions for these changes have been added to the remarks field for the applicable drugs in the SEER*RX Interactive Drug Database (


    http://seer.cancer.gov/tools/seerrx/).

Codes (Refer to the most recent STORE and SEER Rx for complete coding instructions.) 

    
        
            00
            None, immunotherapy was not part of the planned first course of therapy; not customary therapy for this cancer. Diagnosed at autopsy.
        
        
            01
            Immunotherapy administered as first course therapy.
        
        
            82
            Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.) or there was progression of disease prior to administration.
        
        
            85
            Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
        
        
            86
            Immunotherapy was not administered. It was recommended by the patient's physician but was not administered as part of the first-course of therapy. No reason was noted in the patient record.
        
        
            87
            Immunotherapy was not administered. It was recommended by the patient's physician but was refused by the patient or the patient's family or guardian. The refusal was noted in the patient record.
        
        
            88
            Immunotherapy was recommended, but it is unknown if it was administered.
        
        
            99
            It is unknown if immunotherapy was recommended or administered because it was not stated in the patient record. Death certificate-only case.
        
    


    Note: For tumors diagnosed on or after January 1, 2003, information on bone marrow and stem cell transplants is no longer coded under this item. ROADS codes 02-06 should not be used in this field. For diagnosed on or after January 1, 2003, this information should be coded in the new field RX SUMM--Transplnt/Endocr [3250].

00	None, immunotherapy was not part of the planned first course of therapy; not customary therapy for this cancer. Diagnosed at autopsy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, etc.) or there was progression of disease prior to administration.
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician but was not administered as part of the first-course of therapy. No reason was noted in the patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician but was refused by the patient or the patient's family or guardian. The refusal was noted in the patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown if immunotherapy was recommended or administered because it was not stated in the patient record. Death certificate-only case.